 | |
| Clinical data | |
|---|---|
| Other names | G5; Ganesha-5; GANESHA-5; 3C-G-5; 3,4-Norbornyl-2,5-dimethoxyamphetamine; 3,6-Dimethoxy-4-(2-aminopropyl)benzonorbornane; DOG-5 |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic;Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Onset of action | Very slow[1] |
| Duration of action | 16–30 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C16H23NO2 |
| Molar mass | 261.365 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
G-5, also known as3,4-norbornyl-2,5-dimethoxyamphetamine, is apsychedelic drug of thephenethylamine,amphetamine, andDOx families.[1][2][3] It is one of severalhomologues ofGanesha (G).[1][2][3]
In his bookPiHKAL (Phenethylamines I Have Known and Loved) and other publications,Alexander Shulgin lists G-5's dose as 14 to 20 mgorally and itsduration as 16 to 30 hours.[1][2][3] It is said to have a very slowonset.[1] The effects of G-5 were reported to include an unexpected absence ofvisual and relatedsensory activity, excellent mental activity, "absence of the bells and whistles that are expected with a psychedelic in full bloom", mental integration, and little or nobody load.[1] Per Shulgin, it was somehow lacking in characteristics that would've made it fully favorable, perhaps the lack of perceptual effects, which resulted in there being little drive to further explore it.[1]
The drug is not amonoamine releasing agent of eitherserotonin ordopamine.[4] Thechemical synthesis of G-5 has been described.[1]
G-5 was first described in the literature by Shulgin and colleagues in 1991.[1][4] It is acontrolled substance inCanada under phenethylamine blanket-ban language.[5]
 | Thishallucinogen-related article is astub. You can help Wikipedia byadding missing information. |